

41

1644



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Examining Operations

Applicant(s): Mosca, et al.

Serial No: 09/267,456 ✓

Art Unit: 1644 ✓

Filed: March 12, 1999

Examiner: Ewoldt

Title: Mesenchymal Stem Cells as Immunosuppressants

Attorney

Docket No.: 640100-295

Customer No. 27162

TRANSMITTAL LETTER

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RECEIVED

JUL 17 2003

TECH CENTER 1600/2900

SIR:

Enclosed please find the following:

1. Amendment; and
2. A self-addressed, postage paid, return receipt postcard, date stamp and return of which is respectfully requested.

The Commissioner is authorized to charge payment of any additional filing fees required under 37 C.F.R. 1.16 associated with this communication or credit any overpayment to Deposit **Account No. 03-0678**.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Raymond J. Lillie 7/10/03
Raymond J. Lillie, Esq. Date

Respectfully submitted,

Raymond J. Lillie
Raymond J. Lillie, Esq.
Reg. No. 31,778

CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, New Jersey 07068
T: (973) 994-1700
F: (973) 994-1744



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Mosca, et al.
Serial No.: 09/267,456
Filed: March 12, 1999
For: Mesenchymal Stem Cells as Immunosuppressants
Group: 1644
Examiner: Ewoldt

Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

AMENDMENT

SIR:

This is an Amendment in response to the Office Action dated April 24, 2003.

A. Introductory Comments:

Cancel Claims 21-36 without prejudice and add Claims 37-59 as shown hereinbelow.

The fact that Claims 21-36 have been cancelled without prejudice is not to be construed as an admission by Applicants or Applicants' attorney that such claims are not patentable, and Applicants reserve the right to prosecute such claims in a continuing application.